Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
NCT ID: NCT01661790
Last Updated: 2015-03-25
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
72 participants
INTERVENTIONAL
2009-08-31
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
NCT02942043
Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer
NCT02054052
Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC
NCT00250978
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
NCT01644994
Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC
NCT02005120
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bevacizumab & Cisplatin
Bevacizumab 300mg plus Cisplatin 30mg by intrapleural given every two weeks
Bevacizumab
Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
Cisplatin
Cisplatin 30mg,intrapleural administration,each 2 week
Cisplatin
Cisplatin 30mg by intrapleural given every two weeks
Cisplatin
Cisplatin 30mg,intrapleural administration,each 2 week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
Cisplatin
Cisplatin 30mg,intrapleural administration,each 2 week
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Karnofsky performance status (KPS) ≥60
* Life expectancy ≥ 2 months
* No history of severe diseases of major organs including liver, heart, and kidney
* No previous intrapleural therapy
* Written informed consent
Exclusion Criteria
* Active pleural or systemic infection.
* Known sensitivity to Bevacizumab or Cisplatin
* Refusal to participate in the study.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roche Pharma AG
INDUSTRY
Chinese PLA General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
DuNan
director of oncology department in PLA 304 hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nan Du
Role: PRINCIPAL_INVESTIGATOR
PLA 304 hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PLA 304 hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PLA304DN-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.